Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current HIV/AIDS Reports
Published in: Current HIV/AIDS Reports 3/2015

01-09-2015 | Co-infections and Comorbidity (S Naggie, Section Editor)

Emerging Challenges in Managing Hepatitis B in HIV Patients

Authors: Vincent Soriano, Pablo Labarga, Carmen de Mendoza, José M. Peña, José V. Fernández-Montero, Laura Benítez, Isabella Esposito, Pablo Barreiro

Published in: Current HIV/AIDS Reports | Issue 3/2015

Login to get access

Abstract

Roughly 10 % of HIV-positive individuals worldwide have concomitant chronic hepatitis B virus (HBV) infection, with large differences between geographical regions and/or risk groups. Hepatitis B is a preventable infection with vaccines. However, it cannot be eradicated once acquired, resembling HIV and in contrast with HCV. In developed countries, hepatitis B exhibits particular features in the HIV population. First, HBV infection is less frequently misdiagnosed than in the general population. Second, nucleos(t)ide analogs active against HBV are widely used as part of antiretroviral combinations and are taken by most HIV patients. Lastly, as the HIV population ages given the success of antiretroviral therapy, non-AIDS co-morbidities are becoming a major cause of disease, for which specific drugs are required, increasing the risk of interactions and hepatotoxicity. Furthermore, concern on HBV reactivation is rising as immunosuppressive drug therapies are increasingly been used for cancers and other non-malignant conditions. In this scenario, new challenges are emerging in the management of hepatitis B in HIV-positive individuals. Among them, major interest is focused on failures to suppress HBV replication, HBV breakthroughs and reactivations, the meaning of isolated anti-HBc, screening for liver cancer, and the complexity arising when hepatitis viruses C and/or D are additionally present. This review will focus on these challenges and the major advances in HBV coinfection in HIV.
Literature
1.
Soriano V, Puoti M, Peters M, et al. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B virus international panel. AIDS. 2008;22:1399–410.PubMedCrossRef
2.
Thio C. Hepatitis B, and Human immunodeficiency virus coinfection. Hepatology. 2009;49(suppl):138–45.CrossRef
3.
Soriano V, de Mendoza C, Fernandez-Montero JV, Labarga P, Barreiro P. Management and treatment of chronic hepatitis B in HIV-positive patients. Ann Med. 2014;46:290–6.PubMedCrossRef
4.
Kellerman S, Hanson D, McNaghten A, Fleming P. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in HIV-infected participants. J Infect Dis. 2003;188:571–7.PubMedCrossRef
5.
Konopnicki D, Mocroft A, de Wit S, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to HAART and increased mortality in the EuroSIDA cohort. AIDS. 2005;19:2117–25.CrossRef
6.•
WHO. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. March 2015 (www.​who.​int) This document is an updated comprehensive report on the prevention, management and treatment of hepatitis B, with special focus on developing regions. Non-invasive methods for assessing liver fibrosis are overtly recommended instead of liver biopsies whereas tenofovir or entecavir are preferred over lamivudine as HBV therapy.
7.•
Modi A, Feld J. Viral hepatitis and HIV in Africa. AIDS Rev. 2007;9:25–39. This is one of the most comprehensive reviews on the epidemiology of viral hepatitis in Africa and its overlap with the HIV epidemic.
8.
Geretti AM, Patel M, Sarfo F, et al. Detection of highly prevalent HBV co-infection among HIV-seropositive persons in Ghana. J Clin Microbiol. 2010;48:3223–30.PubMedCentralPubMedCrossRef
9.
Chun H, Fieberg A, Hullsied K, et al. Epidemiology of Hepatitis B virus infection in a US cohort of HIV-infected individuals during the past 20 years. Clin Infect Dis. 2010;50:426–36.PubMedCentralPubMedCrossRef
10.
Te H, Jensen D. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis. 2010;14:1–21.PubMedCrossRef
11.
12.
13.
14.
Gunthard H, Aberg J, Eron J, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA panel. JAMA. 2014;312:410–25.PubMedCrossRef
15.•
Thio C, Seaberg E, Skolasky R, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002;360:1921–6. This is a pivotal study demonstrating that HIV worsts the natural history of chronic hepatitis B.
16.
Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Krastev Z, et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci (in press).
17.•
Martín-Carbonero L, Teixeira T, Poveda E, et al. Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues. AIDS. 2011;25:73–9. This study reports HBV outcomes in one of the largest series of HIV-HBV coinfected individuals followed for the longest follow-up on tenofovir-containing regimens.
18.
Koklu S, Tuna Y, Gulsen M, et al. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis. Clin Gastroenterol Hepatol. 2013;11:88–94.PubMedCrossRef
19.•
Boyd A, Gozlan J, Maylin S, et al. Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications. Hepatology. 2014;60:497–507. This study reported a 10% rate of low-level HBV-DNA in 111 HIV-HBV coinfected patients treated with tenofovir and followed for more than 6 years.
20.
Sheldon J, Camino N, Rodes B, et al. Selection of hepatitis B virus polymerase mutations in HIV coinfected patients treated with tenofovir. Antivir Ther. 2005;10:727–34.PubMed
21.
Liu Y, Fung S, Gane E, et al. Evaluation of HBV-DNA decay kinetics in patients containing both rtM204V/I mutant and wild-type HBV subpopulations during tenofovir DF (TDF) monotherapy or combination therapy with emtricitabine (FTC)/TDF. J Med Virol. 2014;86:1473–81.PubMedCrossRef
22.
Fung S, Kwan P, Fari M, et al. Randomized comparison of tenofovir vs emtricitabine and tenofovir in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2014;146:980–8.PubMedCrossRef
23.
Corsa A, Liu Y, Flaherty J, et al. No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B. Clin Gastroenterol Hepatol (in press).
24.
Plaza Z, Aguilera A, Mena A, et al. Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B. AIDS. 2013;27:2219–24.PubMedCrossRef
25.
Boyd A, Moh R, Gabillard D, et al. Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV co-infected patients from Cote d’Ivoire. Antivir Ther 2015 (in press).
26.
Hoffmann C, Charalambous S, Martin D, et al. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis. 2008;47:1479–85.PubMedCentralPubMedCrossRef
27.
Soriano V, Rivas P, Nuñez M. Risks and benefits of using antiretroviral therapy in HIV-infected patients with chronic hepatitis B in developing regions. Clin Infect Dis. 2008;47:1486–9.PubMedCrossRef
28.
Thibault V, Aubron-Olivier C, Agut H, Katlama C. Primary infection with a lamivudine-resistant hepatitis B virus. AIDS. 2002;16:131–3.PubMedCrossRef
29.
Tuma P, Pineda J, Labarga P, et al. HBV primary drug resistance in newly diagnosed HIV-HBV-coinfected individuals in Spain. Antivir Ther. 2011;16:585–89.PubMedCrossRef
30.
Kouanfack C, Aghokeng A, Mondain A, et al. Lamivudine-resistant HBV infection in HIV-positive patients receiving antiretroviral therapy in a public routine clinic in Cameroon. Antivir Ther. 2012;17:321–6.PubMedCrossRef
31.
Velasco M, Morán A, Téllez MJ. Resolution of chronic hepatitis B after ritonavir treatment in an HIV-infected patient. N Engl J Med. 1999;340:1765–6.PubMedCrossRef
32.
Crane M, Oliver B, Matthews G, Avihingsanon A, Ubolyam S, Markovska V, et al. Immunopathogenesis of hepatic flare in HIV/HBV-coinfected individuals after the initiation of HBV-active antiretroviral therapy. J Infect Dis. 2009;199:974–81.PubMedCrossRef
33.
Soriano V, Puoti M, Garcia-Gascó P, et al. Antiretroviral drugs and liver injury. AIDS. 2008;22:1–13.PubMedCrossRef
34.
Dore G, Soriano V, Rockstroh J, Kupfer B, Tedaldi E, Peters L, et al. Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption. AIDS. 2010;24:857–65.PubMedCentralPubMedCrossRef
35.
Berg T, Simon K, Mauss S, Schott E, Heyne R, Klass D, et al. Stopping tenofovir treatment after long-term virologic suppression in HBeAg-negative CHB: week 48 interim results from an ongoing randomized, controlled trial (FINITE CHB) [abstract O-119]. J Hepatol. 2015;62(suppl):253.CrossRef
36.
Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS. 2009;23:689–96.PubMedCrossRef
37.
Del Palacio M, Romero S, Casado JL. Proximal tubular renal dysfunction or damage in HIV-infected patients. AIDS Rev. 2012;14:179–87.PubMed
38.
Rifkin B, Perazella M. Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. Am J Med. 2004;117:282–4.PubMedCrossRef
39.
Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in HIV-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis. 2003;36:1070–3.PubMedCrossRef
40.
Bedimo R, Maalouf N, Zhang S, Drechsler H, Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS. 2012;26:825–31.PubMedCrossRef
41.
Wands J, Chura C, Roll F, et al. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology. 1975;68:105–12.
42.•
Perrillo R, Martin P, Lok A. Preventing hepatitis B reactivation due to immunosuppressive drug regimens. JAMA (in press). This editorial briefly updates which circumstances may prone to hepatitis B reactivation and how to prevent it.
43.
Yeo W, Johnson P. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006;43:209–20.PubMedCrossRef
44.
Seto W, Chan T, Hwang Y, Wong D, Liu K, Gill H, et al. A prospective study of hepatitis B reactivation in patients with prior HBV exposure undergoing hematopoietic stem cell transplantation: reactivation association with graft-versus-host disease [abstract O-009]. J Hepatol. 2015;62(suppl):194.CrossRef
45.
Milazzo L, Ebranati E, Cattaneo D, et al. Recurrence of another hepatitis B virus escape mutant comes back in a patient infected with HIV and low CD4+ count. J Med Virol. 2014;86:97–101.PubMedCrossRef
46.
Pei R, Grund S, Verheyen J, Esser S, Chen X, Lu M. Spontaneous reactivation of hepatitis B virus replication in an HIV coinfected patient with isolated anti-hepatitis B core antibodies. Virol J. 2014;11:9.PubMedCentralPubMedCrossRef
47.
Soriano V, McMahon B. Strategic use of lamivudine in the management of chronic hepatitis B. Antivir Res. 2013;100:435–8.PubMedCrossRef
48.•
McMahon B, Jilek B, Brennan T, et al. The HBV drug entecavir—effects on HIV-1 replication and resistance. N Engl J Med. 2007;356:2614–21. This was the first report of the unexpected weak antiretroviral effect of entecavir and the risk for selection of drug resistance mutations in HIV.
49.
Koskinas J, Tampaki M, Doumba P, Rallis E. Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in a HBsAg-negative anti-HBs + patient. Br J Dermatol. 2013;168:679–80.PubMedCrossRef
50.
López-Serrano P, de la Fuente E, Carrera E, Pérez-Calle J, Fernández C. Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: when and how to apply prophylaxis, with a special focus on corticosteroid therapy. World J Hepatol. 2015;7:539–47.PubMedCentralPubMedCrossRef
51.
Tamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H, et al. Prospective study of reactivation of HBV in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol. 2011;46:556–64.PubMedCrossRef
52.
53.
54.
Kane M. Global programme for control of hepatitis B infection. Vaccine. 1995;13(suppl):47–9.CrossRef
55.
World Health Organization. Hepatitis B vaccines: WHO position paper. Wkly Epidemiol Rec. 2009;84:405–19.
56.
Rivas P, Herrero MD, Puente S, Ramírez-Olivencia G, Soriano V. Immunizations in HIV-infected adults. AIDS Rev. 2007;9:173–87.PubMed
57.
Fonseca M, Pang L, de Paula-Cavalheiro N, Barone A, Heloisa-Lopes M. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine. 2005;23:2902–8.PubMedCrossRef
58.
Launay O, van der Vliet D, Rosenberg A, et al. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. JAMA. 2011;305:1432–40.PubMedCrossRef
59.
Roni D, Pathapati R, Kumar A, Nihal L, Sridhar K, Tumkur RS. Safety and efficacy of hepatitis B vaccination in cirrhosis of liver. Adv Virol. 2013;20:196704.
60.
Witt M, Lewis R, Rieg G, Seaberg E, Rinaldo C, Thio C. Predictors of the isolated hepatitis B core antibody pattern in HIV-infected and -uninfected men in the multicenter AIDS cohort study. Clin Infect Dis. 2013;56:606–12.PubMedCentralPubMedCrossRef
61.
Gandhi R, Wurcel A, Lee H, et al. Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. J Infect Dis. 2005;191:1435–41.PubMedCrossRef
62.
Wang Q, Semmo N. T and B cell responses and previous exposure to hepatitis B virus in “anti-HBc alone” patients [abstract O-010]. J Hepatol. 2015;62(suppl):194–5.CrossRef
63.
Locarnini S, Hatzakis A, Chen D, Lok A. Strategies to control hepatitis B: public policy, epidemiology, vaccine and drugs. J Hepatol. 2015;62(suppl):76–86.CrossRef
64.
Whitaker J, Rouphael N, Edupuganti S, Lai L, Mulligan M. Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1. Lancet Infect Dis. 2012;12:966–76.PubMedCentralPubMedCrossRef
65.•
Chen C, Yang H, Su J, et al. Risk of hepatocellular carcinoma across biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73. This manuscript derives from the REVEAL-HBV study and reported for the first time a strong positive direct correlation between baseline serum HBV-DNA and the risk of liver cancer in chronic hepatitis B patients.
66.
Wu C, Lin J, Ho H, Su C, Lee T, Wang S, et al. Association of nucleoside analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B—a nationwide cohort study. Gastroenterology. 2014;147:143–51.PubMedCrossRef
67.
Clifford G, Rickenbach M, Polesel J, et al. Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS. 2008;22:2135–41.PubMedCrossRef
68.
Fernández-Montero JV, Soriano V. Management of hepatitis C in HIV and/or HBV co-infected patients. Best Pract Res Clin Gastroenterol. 2012;26:517–30.PubMedCrossRef
69.
Zhou J, Dore G, Zhang F, Lim P, Chen Y, Asia TREAT, et al. Hepatitis B and C virus coinfection in the TREAT Asia Observational database. J Gastroenterol Hepatol. 2007;22:1510–8.PubMedCrossRef
70.
Pontisso P, Ruvoletto M, Fattovich G, Chemello L, Callorini A, Ruol A, et al. Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterology. 1993;105:1529–33.PubMedCrossRef
71.
Chu C, Lee S. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol. 2008;23:512–20.PubMedCrossRef
72.
Soriano V, Barreiro P, Martin-Carbonero L, et al. Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis. J Infect Dis. 2007;195:1181–3.PubMedCrossRef
73.
Liu C, Chen P, Lai M, Kao J, Jeng Y, Chen D. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology. 2003;37:568–76.PubMedCrossRef
74.
Liu C, Chuang W, Lee C, et al. Peginterferon alfa-2b plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology. 2009;136:496–504.PubMedCrossRef
75.•
Collins J, Raphael K, Terry C, et al. Hepatitis B reactivation during successful treatment of hepatitis C with sofosbuvir and simeprevir. Clin Infect Dis (in press) This study records for the first time two cases of HBV reactivation during successful DAA therapy for hepatitis C.
76.
Wedemeyer H, Heidrich B, Manns M. Hepatitis D virus infection – not a vanishing disease in Europe! Hepatology. 2007;45:1331–2.PubMedCrossRef
77.
Soriano V, Grint D, d’Arminio-Monforte A, et al. Hepatitis delta in HIV-infected individuals in Europe. AIDS. 2011;25:1987–92.PubMedCrossRef
78.
Calle-Serrano B, Manns M, Wedemeyer H. Hepatitis delta and HIV infection. Semin Liver Dis. 2012;32:120–9.PubMedCrossRef
79.
Kew M. Hepatitis viruses (other than hepatitis B and C viruses) as causes of hepatocellular carcinoma: an update. J Viral Hepat. 2013;20:149–57.PubMedCrossRef
80.
81.•
Fernández-Montero JV, Vispo E, Barreiro P, Sierra-Enguita R, de Mendoza C, Labarga P, et al. Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients. Clin Infect Dis. 2014;58:1549–53. This large study highlights the deleterious impact of hepatitis delta on HIV-positive individuals in comparison with coinfection with other hepatitis viruses (B and C).
82.
Erhardt A, Gerlich W, Starke C, et al. Treatment of chronic hepatitis D with pegylated interferon-alpha 2b. Liver Int. 2006;26:805–10.PubMedCrossRef
83.
84.
Farci P, Roskams T, Chessa L, et al. Long-term benefit of interferon as therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology. 2004;126:1740–9.PubMedCrossRef
85.
Niro G, Ciancio A, Gaeta G, et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis D. Hepatology. 2006;44:713–20.PubMedCrossRef
86.
Yurdaydin C, Bozkaya H, Onder F, et al. Treatment of chronic D hepatitis with lamivudine vs lamivudine + interferon vs interferon. J Viral Hepat. 2008;15:314–21.PubMedCrossRef
87.
Wedemeyer H, Yurdaydìn C, Dalekos G, HIDIT Study Group, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011;364:322–31.PubMedCrossRef
88.
Wedemeyer H, Port K, Heidrich S, et al. 96 weeks of pegylated interferon alpha-2a plus tenofovir or placebo for the treatment of hepatitis delta: the HIDIT-2 study. Washington DC: AASLD; 2013 [abstract 31].
89.
Mansour W, Ducancelle A, Le Gal F, et al. Resolution of chronic hepatitis Delta after 1 year of combined therapy with pegylated interferon, tenofovir and emtricitabine. J Clin Virol. 2010;47:97–9.PubMedCrossRef
90.
James G, Sidhu P, Raza M. First report of successful clearance of hepatitis B and D coinfection with tenofovir monotherapy. Hepatology (in press).
91.
Sheldon J, Ramos B, Toro C, et al. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients? Antivir Ther. 2008;13:97–102.PubMed
92.
Soriano V, Vispo E, Sierra-Enguita R, et al. Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients. AIDS. 2014;28:2389–94.PubMedCrossRef
93.
Soriano V, Barreiro P, de Mendoza C. Tenofovir for hepatitis delta. Hepatology (in press).
94.
Farci P. Treatment of chronic hepatitis D: new advances, old challenges. Hepatology. 2006;44:536–9.PubMedCrossRef
95.
Roche B, Samuel D. Liver transplantation in delta virus infection. Semin Liver Dis. 2012;32:245–55.PubMedCrossRef
96.
Ni Y, Lempp F, Mehrle S, et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology. 2014;146:1070–83.PubMedCrossRef
97.
Zoulim F, Durantel D. Antiviral therapies and prospects for a cure of chronic hepatitis B. Cold Spring Harb Perspect Med. 2015;5:a021501.PubMedCrossRef
98.
Yurdaydin C, Idilman R, Choong I, et al. Optimizing the prenylation inhibitor lonafarnib using ritonavir boosting in patients with chronic delta hepatitis. EASL, Vienna, April 2015 [abstract O118]. J Hepatol. 2015;62(suppl):252.CrossRef
99.
Schirmera P, Wintersb M, Holodniy M. HIV-HBV vaccine escape mutant infection with loss of HBV surface antibody and persistent HBV viremia on tenofovir/emtricitabine without antiviral resistance. J Clin Virol. 2011;52:261–4.CrossRef
100.
Pal A, Sarkar N, Saha D, et al. High incidence of lamivudine-resistance associated vaccine-escape HBV mutant among HIV-coinfected patients on prolonged antiretroviral therapy. Antivir Ther (in press).
Metadata
Title
Emerging Challenges in Managing Hepatitis B in HIV Patients
Authors
Vincent Soriano
Pablo Labarga
Carmen de Mendoza
José M. Peña
José V. Fernández-Montero
Laura Benítez
Isabella Esposito
Pablo Barreiro
Publication date
01-09-2015
Publisher
Springer US
Published in
Current HIV/AIDS Reports / Issue 3/2015
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-015-0275-7

Other articles of this Issue 3/2015

Current HIV/AIDS Reports 3/2015 Go to the issue

Erratum

Erratum to: Southern Africa: the Highest Priority Region for HIV Prevention and Care Interventions

Complications of Antiretroviral Therapy (JM Kilby, Section Editor)

The Role of Statins in the Setting of HIV Infection

Co-infections and Comorbidity (S Naggie, Section Editor)

The Role of Viral Co-Infection in HIV-Associated Non-AIDS-Related Cancers

Co-infections and Comorbidity (S Naggie, Section Editor)

Drug Interactions of Hepatitis C Direct-Acting Antivirals in the HIV-Infected Person

Co-infections and Comorbidity (S Naggie, Section Editor)

Acute HCV in HIV-Infected MSM: Modes of Acquisition, Liver Fibrosis, and Treatment

Co-infections and Comorbidity (S Naggie, Section Editor)

Treatment of Chronic HCV Genotype 1 Coinfection
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits